ArticlePharmaceuticals (Basel, Switzerland)2025

SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic.

Mohamad Suki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.